<SEC-DOCUMENT>0001493152-24-033368.txt : 20240821
<SEC-HEADER>0001493152-24-033368.hdr.sgml : 20240821
<ACCEPTANCE-DATETIME>20240821070014
ACCESSION NUMBER:		0001493152-24-033368
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240821
FILED AS OF DATE:		20240821
DATE AS OF CHANGE:		20240821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		241227185

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>August
2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2024, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing today that it has been notified that Panetta
Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 35,000 of the Company&rsquo;s
ordinary shares on NASDAQ at a price of US$1.00 per share. This brings the total shareholding of Mr Cerrone to 9,671,570 shares which
is 28.58% of issued share capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 21, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">News Announcement, dated August 21, 2024</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Announces Chairman Acquires Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
and New York, NY, August 21, 2024</B> &ndash; OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing
innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular
segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy,
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced today that it has been notified that Panetta
Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 35,000 of the Company&rsquo;s
ordinary shares on NASDAQ at a price of US$1.00 per share. This brings the total shareholding of Mr Cerrone to 9,671,570 shares which
is 28.58% of issued share capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OK-101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel
long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy
signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through
the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment.
OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled
trial of OK-101 to treat DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED
and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel
molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway
for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please
visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enquiries:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 26%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma Limited</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 38%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 32%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Development &amp; Investor Relations</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
    (0)20 7495 2379</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% 2P# 2(  A$! Q$!_\0
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M5;2/[;JVK:3J>GWMK?SR*=:U35(+K5[C\QK_ /X*._M^ZG</<:E^WY^V/-=
M[7D?]J7XU)*,<"-T@\=1^5MYQ%Y,2 @L!DUR_P"QO\'-'_:._:\_97_9_P#$
MMS?6GA7XT?M#?"#X:^+9=,N'M-3B\&>)_'.D6'C)='O$61M/U>?PP^KQ:9?K
M&XT_4)(+PQMY1!_UH? G[!_[%7PZ\/Z7X3\&_LE_LXZ%H&BZ=;:7IUE!\&_
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M*454<4I1E=1]G-N<(N[E#7FI_P <7_!LAX<_X)K:U^TQ>2_M.W$EY^V/9ZG
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M<'@XZ$9)!(LV'_!R7_P1]U2[M;5/VG-;T_S9E47.J?!'XTZ?90E\A9+F\N?
M\=O;P#()DE.U5^8LI&]>.7"G$ZC.3X?SF*A%N4GEV*7)[O-=M0E;1-.ZT3=[
M69TQS[)9SA&.;9:W)[_7*"?NRM[MY1NY/1;77DS_ #BOVU;B(?ME?M;@RH#_
M ,--?'0-DD8(^)?B4$9XY/0D$KS@$&O])'_@VSVG_@BS^QJ4.Y3-^TBP/."&
M_:V^/!R,@'!SD>W3CFOT-^&/@_\ 8J_:+\$Z%\:?A7X _9M^+G@3XAPW7B#1
M/B-X=^'WP^\1Z?XI>2[G34K]]5_L226;4%U..ZAU1;QSJ$.HI<07Z17D<R#Y
M>_:2_P""K'_!.K_@G#\8/A9^R-\8_&%K\%O$7CC1=*\4>'-$\*?"S7H_AGX*
M\,^-O%VO:/8^(O%VN>%-$'A/P1I.J^*].\17.HWERZ?9/*O==UI+:SG?4'^S
MXDXNQ7&6599PY@>'L9#%Y7R5JKHREBJTEEV"^JXF3PE/"TZU**C'VU1S;]E&
M*BU*35_G<DX<I</8[&9UB,TPTZ&8PJ**E:E",L3B?K,/WTJCIU':\%RM\]FX
MW2L?J_7S_P#M1_ 7PA^U+^S_ /&/]G/Q\TT?@_XT?#CQ-\/M;NK> 7-QIT7B
M&PFM;;6;:W\R$W%UHM\+;4[:V,T*SSV\<1EC#%U]TLKR.\@2=)(720!H9(95
MEBGA=5>*>%U)5X9T820NK,LD3)(C,K@U+(/FR>FW &,\Y)YYZ8'ISVK\PA5J
M4:E*M1DZ=6C5IU85+-3I3I3C4A4BI1DN>G.G"5IQ2TDI6V/N)0C4C.G-*4)Q
MG"<7M.,HRA*-TTTI1D[2B^9)IQ[K_(,_;8_X)H_MB?\ !/[XAZUX!^/?PB\5
M-X>@U34]/\)?&7POH>I>(O@]\3]$MG=K'Q#X6\4Z?9W%K:37^G/#>ZGX2\3#
M2/%GA^6=[/6-%BB6WO;[QKPA^V7^U]\,/#^F>#_ 7[67[37P_P#"NA6<.F:+
MX1\,_'7XJ^'_  ]H>G6JA+;3=(T.V\41:?I=C:1*D-K8V%I;VMO"B1P11HH0
M?ZL_[>G_  42_9(_X)W> O"WC+]JWQW=^'-(^(FLW?A3PEX8T/PGK?CWQ3XM
MNK2T2ZUN2P\(>'['4+R[TC1;*:"77=2NXH=-L%O+*VFF:\O[*UN?0/A+X7_9
M'_:8^%WPY^.O@7X4?!OQMX ^+/@GP[\0O!'B34_A%X7BO-5\,^*=,MM4TB\N
M;+6_#T.IZ;=/:7*+=Z=?00WEC<K+;7"B2-E'[?A_%7'?V9AL5GO"<<=0K3>%
MI9G"%+#X''8C#QA4K^Q6.PF,C#$PYJ=2<\).--1<X6EK&'Y=B. ,.\?6CE6?
M5,#5?[VK@H\TJM&A)V@I.AB(5/9QE*T'5CS*$H)QDDG'_*!_X>'?MXGI^W'^
MUOT_A_:+^+1) ^OBM!V]?8#FJUS^W_\ MUZA$]M<_MN_M=7,4HVM$?VC?BY'
M\IPVT/!XQ61.?FR&!!P<@@5_KC2?LP_LV* ?^&>O@4<L <_"+P 1C!)./[!Y
M/'_UJ_)_]LK_ (*-_P#!&C_@G]\7;+X)?'[P]\+=#^*4FD:=XCUK0OAW^S#!
M\1;GP/HNLPFYT>_\<W'@SP7J47AN?5+#;JMCI=TSZS<:/+;ZO'8'3+F"[DZ<
M'XEX',*ZP^7^'\\;B>2=54L-++\144*:]ZHXPR234(W7,VTE=+XI04LJ_ N,
MPM/VV(XNGAX.2@JE6>+A#G?PQ;GC(+FEKRQNG+97V?\ FI?!S]GW]H7]I3Q[
M:^ _@?\ "'XI_&7XA>*[Z_O8]'\)>&];U_4=1N+AY+S4M8UCQ!?YT^QMH#)/
M>ZMXD\4:O9V-J"MQ?W[O*7;_ $O?^"-?_!)K1/V$/V+-#^%_QYT?PWXQ^./C
MOQKKOQA^*S6-P^IZ)X5\4>*M$\+Z#:^!="U2%[>+5;/PGX7\(^'=+O\ 5;='
ML]4\0QZWJ&G2R:=<VAK]@_AIJ?P^\0>"/"GB;X577A2^^'GB[1=*\5^$M6\#
M)IB^%_$/A_7K*WO](UW1Y='C@L;JQU/3I;6ZM[B!&62!X\,ZC%>A>7UY[D]/
M7\:^(XO\1<TXBHT\NH8)9-@Z%?GK4J%:K/$U*]&4X0A6E56&5.-!.4?9480B
MJJFI*\'"/T^0<'8')*L\9+$2S#%5Z2BZLHP5/DJ*$I2C"\^:53D@_:2E*3BE
MU]XDKY0_;'_9#^%?[;'P$\9? +XP6LTFA^)52_\ #WB33XHQX@\ >-=-25_"
M_CGPS.2GDZQH%W*Y,3.MOJ^F7%_H>IB?3M0NXI?J^D*JW# $=>0#S@C//L2/
MH37PF#Q>*R_&87,,#B*V$QV"KT\3A,7AZDJ5?#8BC.-2E6HU(M2A.$HIIZIJ
MZE"<92B_JL1AZ&+H5L-B:5.OA\12G1KT*L(U*56E5BX5*=2$XRC*,HR:=U=)
MW3BTI+_-ANO$7[>G_!%3]K#Q;\/O"_B^]^'WBO3I+?5)+*6RF\1_ [X__#Z:
M\F;1O%)\+:LQL=6T#6&:>VN[_19_#GC?P9K-OJ_AFWU[0=3AEN;O^F;]CG_@
MXU_9<^+=II/A;]J/1;G]F+X@ND%M<>(YI]0\7?!O5M1<)&TEAXEM+23Q#X7B
MNY6:2*T\4:.++38 WVOQ%-;1?;I/U+_;Q_X)_P#P/_;_ /A'-\-?B_8R:;KF
MC2ZCJ7PQ^*.B0VP\:?"_Q)?0B%M2T.XN%V7NC:@D5K;>)_"U[)_9?B"QA5)C
M:WEOI^H6'^?G^V[_ ,$_?VDOV O'DGA7XW^%9[OP=J=]<P^ ?C7X>M+^[^&'
MC^U2>4V45MK<L;KX8\4M;[);SP-XCFMM;L"7>Q;6-(C36I_ZGX?Q'A]XUX2C
M@^)Z2R;Q H4*5">/P#H83%9U*%-1^M87]VJ&92J1HTW7P6,A4Q&#JRJO#U,3
M@Y4EA_YZSFAQEX5XBIB>'JT\RX.Q%5U*668RCB,90RARG.57"U:ZJ5<1@:=F
MGA<=2JPPE9/EQ5*GC/:U,9_I?^"_B#X'^*'AVS\8?#?QAX5^('A+5 PT[Q7X
M(\1:1XJ\.WGEXW_9-9T*[OM/GDCW)YL:W!:,L!(H/RGQ[XS?LC?LX?M"2I>?
M%[X3^'O%&L01K%%XFMIM:\)^,8X8VW1VZ>,/!>J>'?%'V93G= -6$#98>2(W
M*#_+^^'?Q)^)GP<UR7Q-\'?B3\1OA#XCN #=:Y\+_&_B;X>ZK>,J%8);V^\(
M:II<NI!(WDCB6\FN8HU9@NT[U'W_ .%?^"RW_!4/PC9V]A9_M@^.-9M[6-(8
M3XN\+?#3Q7=F..-(HQ<ZIK'@F?5+Z0K$&>YO;RXNY96DDGGED=Y&\O'?1RXE
MP&+5?AKBW RJTI15-XBGF64YE1O+:=7!3Q&&Y8^[)5(2C3J33E&E"R2]' ^-
MV0XRE"EG?#^-P\N:'.J+P.:X3GDOXBISE0K13:;C":C6:=HN?Q/^X;P[_P $
MLOV(?#FK6FL'X2:CXDN;*;[3:VOC+XE_%+Q3H:X21/*N?#.I^+Y?#FKVS!N;
M36M+U&UC*(T<*L":][^+GQT_9Q_8R^&$?B?XM>,OA_\  _X;:#:-9Z)9W)T_
M0(;L6QAC31?!GA/2[9-0\0:D6N(4BT7PWI-]>1Q2)/-#%'(9F_S_ #Q?_P %
MD_\ @J!XUTZXTO4?VP?'>BVM[%+!<MX,\.?#CP9J'DS)L=;76?#_ (,LM<TY
MP/\ 57>EZI8WUO)B2&Z0KAOSO\9^,O&/Q%\1S^-?B9XX\8_$;QG=KY%WXT^(
M_B[6_&WBJ>%Y)'%O/XH\5ZAJ&J- TDLK16C7D=JDDL_E1AYY%?MP?T>N*<TK
MT)<:<9JM1IU%&5# ULQSC,(PE4YI057&KZI@IU8MN%:IAZU51DITZ&(44H\N
M/\;.'\NI5%P_PSB:F(G=1K8N&'RW#67OPG/ZNL9BZBDTIQPSJ44TXIJ.K/V)
M_P""K?\ P5C\>?\ !17QCIWP=^$MG??#W]F#0_$]E)X6\.^(M0L/#&L?%CQ@
MTD5IIOCKXHZU=W,-EX2\.Z7<W5ROAS0O[9M;#1+66Y\3^)M0DU5=/M_#'Z.?
M#/\ X+'_ +$__!,S]DOX??LS?LL:1K_[6'CSP?HC:KXM^(=LEY\,OA#XC^)G
MB6ZCU7QEXCF\0>*M+A\6SZ0=2N);#1;?2_!TDL&D:;HEI-/$S37X_GQ_9*_8
M1_:I_;?\2_\ "/?L[?"75_$6C07/V?7_ (G:\MQX6^#WA1D8&?\ M[Q]=VCZ
M=>WL."I\.>&X/$/BF\PSVNARVL4UW!_9W_P3X_X(3?LX_LA7GA_XF?%B>T_:
M._: TF>+4M.\2^*-)A7X<^!=6MXYDM-0\ ^!KY;R%];L=Y-IXL\3S:IJEI<)
M%J.@V^@7D?G/[GB*O"OA/),GX6Q%;$8W#9-/%8Z/!>28NA2Q689O.U"&/XES
MBG+$8FERT/:-K%NA6<JE3V.&IJ.'H4/.X+_XB'Q'F&:Y[1A0P-?-U1H5.)<Y
MP]2=/ Y6N6M# \.Y9.$858*HE%NHG#VM.C*I.5*I6J5?SZ^%_P"S?_P5/_X+
M,2:;XV_;=^*GB#]DG]B[5)[;5]$^!?PUT=? >N?$#2KAK>>&73- U#^T?%=[
MI]S!:VDD/BSXVZMK]M8S7AU#P7X 6*_O&@_I%_9A_8[_ &>?V-_ %I\-/V<O
MAGX=^'/AJ H^H75DEYJGBSQ1=J07U3QIXVUJZU'Q7XMU60@*MWKFKW?V.V2'
M3M/CM=+M;6QA^DXX'!1I,,X8DDG/&2=P)!.[G QC X&!FK=?S-Q#QAF&?THY
M?2PN"R'A[#U%/!<-9)1^I930<4HQKXB,)+$9GCI1C%UL?F=?%8FI.[A'#P<:
M:_<,EX8P64R^MUJN)S;.IP<<5GF:5/K6/K.2]Z&'E.,J67X9-R4,)EM/"8=+
MEC4^LN+D)@#H /PI&Z#_ 'D_]"%.J-VP44\;F')SC(9<+P#RV>.W!SBOD[+Y
M]^KMW9]*?YRW_!$']E;]GO\ :W_X*R?ML_#K]I'X0>#OC=X'T2U^/WBJP\,>
M.]);5=)TGQ!!\?(=,M=:@BCF@$=W':7DUA'-*6Q'<,B$22!C_8D__!$#_@DR
M5S_PP!^SF3A5(7P@X)55"A21J(RIV@-G.5SN5N<_PB_\$^/^";GPF_X*E?\
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ME%+#?5*2HTJV7UJU:$4Y1Y:DX8J$9SNI-R48VNN9*497_DX_X-&KQ+_]L/\
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MJD,PHSE*G26)J0C%4JN!32Q,I2?/0A&K+WFSX-_;Y^*_[6G_  4__P"%^_\
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M%>$_%6MP:E>G4=0AU?Q%H.BV&KZE'?Z@!?WJ7EY,MW>_Z5<+)/\ /7MB8"@
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0*44HJ3@Y**73FMU:;U/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
